Lilly Asia Ventures took part in a $78m round for oncology therapy developer BH Med while gifting platform developer Snappy completed a $70m Hearst-backed series C.

Funding

China-based cancer drug developer BH Med has completed a RMB500m ($78m) series C round featuring Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly, and Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, DealStreetAsia reported on Tuesday. Private equity firm Yunfeng Capital led the round, which included Temasek, 3H Health Investment, Citic Private Equity, Qiming Venture Partners, TF Capital and GL Ventures. It has now raised about $125m according to DealStreetAsia, which named Legend…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn